Depakote (divalproate) — Competitive Intelligence Brief

Depakote (divalproate) (Depakote (divalproate)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Mood stabilizer. Area: Neurology / Psychiatry.

marketed Anticonvulsant / Mood stabilizer GABA metabolism; histone deacetylase inhibition Neurology / Psychiatry Small molecule

Target snapshot

Depakote (divalproate) (Depakote (divalproate)) — Korea Otsuka Pharmaceutical Co., Ltd.. Divalproate increases brain GABA levels and inhibits histone deacetylase, enhancing inhibitory neurotransmission and altering gene expression.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Depakote (divalproate) TARGET	Depakote (divalproate)	Korea Otsuka Pharmaceutical Co., Ltd.	marketed	Anticonvulsant / Mood stabilizer	GABA metabolism; histone deacetylase inhibition
Divalproex (DIV) ER	Divalproex (DIV) ER	The University of Texas Health Science Center at San Antonio	marketed	Anticonvulsant / Mood stabilizer	GABA synthesis enhancement; histone deacetylase inhibition
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Brand lamotrigine	Brand lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine generic "B"	Lamotrigine generic "B"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Low dose lamotrigine	Low dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release modulation
valproate microgranules	valproate microgranules	Sanofi	marketed	Anticonvulsant / Mood stabilizer	Histone deacetylase; GABA metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Mood stabilizer class)

1. University of Maryland, Baltimore · 4 drugs in this class
2. Sanofi · 2 drugs in this class
3. University of Cincinnati · 2 drugs in this class
4. Mario Negri Institute for Pharmacological Research · 1 drug in this class
5. Central Mental Clinic for Outpatients of Baku City · 1 drug in this class
6. The University of Texas Health Science Center at San Antonio · 1 drug in this class
7. University Hospitals Cleveland Medical Center · 1 drug in this class
8. Dhaka Medical College · 1 drug in this class
9. Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class